Arrowhead Pharmaceuticals Inc.Find Ratings Reports
ARROWHEAD PHARMACEUTICALS's gross profit margin for the first quarter of its fiscal year 2020 has significantly decreased when compared to the same period a year ago. Sales and net income have dropped, underperforming the average competitor within its subsector. ARROWHEAD PHARMACEUTICALS is extremely liquid. Currently, the Quick Ratio is 6.83 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 190.65% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY20||Q1 FY19|
|Net Sales ($mil)||29.46||34.66|
|Net Income ($mil)||-2.67||12.04|
|Balance Sheet||Q1 FY20||Q1 FY19|
|Cash & Equiv. ($mil)||502.0||243.75|
|Total Assets ($mil)||587.6||340.95|
|Total Debt ($mil)||14.84||0.0|
|Profitability||Q1 FY20||Q1 FY19|
|Gross Profit Margin||-12.2||34.98|
|Return on Assets||9.06||-8.56|
|Return on Equity||10.65||-16.97|
|Debt||Q1 FY20||Q1 FY19|
|Share Data||Q1 FY20||Q1 FY19|
|Shares outstanding (mil)||101.11||92.59|
|Div / share||0.0||0.0|
|Book value / share||4.95||1.86|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1787943.0||2278298.0|
HOLD. ARROWHEAD PHARMACEUTICALS's P/E ratio indicates a significant premium compared to an average of 31.21 for the Chemical Manufacturing subsector and a significant premium compared to the S&P 500 average of 19.01. To use another comparison, its price-to-book ratio of 5.44 indicates a significant premium versus the S&P 500 average of 2.73 and a significant discount versus the subsector average of 7.80. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average.
|ARWR 49.83||Peers 25.09||ARWR NM||Peers 23.93|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.
ARWR is trading at a significant premium to its peers.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ARWR's P/CF is negative making the measure meaningless.
|ARWR NM||Peers 22.13||ARWR NM||Peers 0.80|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ARWR's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
ARWR's negative PEG ratio makes this valuation measure meaningless.
|ARWR 5.44||Peers 7.80||ARWR 254.28||Peers 82.27|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ARWR is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
ARWR is expected to have an earnings growth rate that significantly exceeds its peers.
|ARWR 16.63||Peers 95.93||ARWR 245.93||Peers 120.57|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ARWR is trading at a significant discount to its subsector on this measurement.
Higher. A sales growth rate that exceeds the subsector implies that a company is gaining market share.
ARWR has a sales growth rate that significantly exceeds its peers.